Fenwick & West represented BioAge Labs, Inc. in the offering, and Cooley represented the underwriters. BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Latham & Watkins advised CARGO Therapeutics, Inc. on the offering, and Cooley advised the underwriters. CARGO Therapeutics, Inc. (CARGO) (Nasdaq:CRGX)...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Neumora, and Cooley advised the underwriters. Neumora Therapeutics, Inc. announced the pricing of its initial public offering of 14,710,000 shares of its common...
You must be a Standard 1 Year member to access this content.
Holland & Knight advised Savara, and Cooley advised the underwriters. Savara announced on July 13, 2023, the pricing of an underwritten offering of 21,000,000 shares of...
You must be a Standard 1 Year member to access this content.
Cooley advised Ionis Pharmaceuticals on the offering. Ionis Pharmaceuticals, a biotechnology company, announced the offering of $575 million aggregate principal amount of convertible senior notes, including the exercise...
You must be a Standard 1 Year member to access this content.
Cooley advised ACELYRIN, and Davis Polk advised the joint book-running managers. ACELYRIN, INC. announced its upsized initial public offering of 34,500,000 shares of common stock at...
You must be a Standard 1 Year member to access this content.
Cooley LLP represented Structure Therapeutics, while Latham & Watkins LLP represented the underwriters in the offering. Structure Therapeutics, a clinical-stage global biopharmaceutical company, announced its $185.3 million...
You must be a Standard 1 Year member to access this content.
Cooley advised Vaxcyte, while Latham & Watkins represented the underwriters on the offering. Vaxcyte, a clinical-stage vaccine innovation company, announced its underwritten public offering of common stock and...
You must be a Standard 1 Year member to access this content.
Cooley advised Route on the deal. Route, a post-purchase experience platform and package tracking company, announced its $200 million Series B financing round, which brings its valuation...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented the underwriters in the offering while Cooley LLP represented sweetgreen. Sweetgreen, Inc. executed its initial public offering of Class A common stock at...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented the underwriters in the offering, while Cooley advised Dutch Bros. McDermott Will & Emery represented Travis Boersma, the Co-Founder of Dutch Bros....
You must be a Standard 1 Year member to access this content.
Latham & Watkins Advises the Underwriters in the offering while Cooley LLP represented Lyell Immunopharma. Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company...
You must be a Standard 1 Year member to access this content.
